The Medical Letter on Drugs and Therapeutics
Duloxetine (Cymbalta) for Diabetic Neuropathic Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Duloxetine hydrochloride (Cymbalta – Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI) available for treatment of depression,1 has also been approved by the FDA for treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN). Duloxetine is one of two drugs approved specifically for management of neuropathic pain due to diabetes; the other, pregabalin (Lyrica – Pfizer), will be marketed soon and will be reviewed in the next issue of The Medical Letter.

OTHER TREATMENTS FOR NEUROPATHIC PAIN — Drugs used to treat neuropathic pain include tricyclic antidepressants, anticonvulsants, opioid analgesics and topical preparations such as capsaicin (Zostrix-HP, and others)2 and lidocaine. Lidocaine 5% transdermal patches (Lidoderm) and gabapentin (Neurontin, and others) are FDA-approved for ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Duloxetine (Cymbalta) for Diabetic Neuropathic Pain
Article code: 1215b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian